Compare Orchid Chemicals with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs TORRENT PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD TORRENT PHARMA ORCHID PHARMA LTD/
TORRENT PHARMA
 
P/E (TTM) x -0.5 58.6 - View Chart
P/BV x 0.1 6.2 1.9% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   TORRENT PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
TORRENT PHARMA
Mar-18
ORCHID PHARMA LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,550 12.5%   
Low Rs351,144 3.1%   
Sales per share (Unadj.) Rs276.5354.7 77.9%  
Earnings per share (Unadj.) Rs-79.240.1 -197.7%  
Cash flow per share (Unadj.) Rs-43.564.2 -67.7%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs53.9273.1 19.7%  
Shares outstanding (eoy) m70.45169.22 41.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.8 10.9%   
Avg P/E ratio x-1.433.6 -4.3%  
P/CF ratio (eoy) x-2.621.0 -12.6%  
Price / Book Value ratio x2.14.9 43.1%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m8,067227,897 3.5%   
No. of employees `0002.814.7 19.0%   
Total wages/salary Rs m2,52711,353 22.3%   
Avg. sales/employee Rs Th6,956.14,083.0 170.4%   
Avg. wages/employee Rs Th902.5772.3 116.9%   
Avg. net profit/employee Rs Th-1,993.0461.3 -432.0%   
INCOME DATA
Net Sales Rs m19,47760,021 32.5%  
Other income Rs m4072,988 13.6%   
Total revenues Rs m19,88463,009 31.6%   
Gross profit Rs m1,10313,493 8.2%  
Depreciation Rs m2,5194,086 61.7%   
Interest Rs m5,2273,085 169.4%   
Profit before tax Rs m-6,2369,310 -67.0%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,529 -5.0%   
Profit after tax Rs m-5,5806,781 -82.3%  
Gross profit margin %5.722.5 25.2%  
Effective tax rate %2.027.2 7.4%   
Net profit margin %-28.711.3 -253.6%  
BALANCE SHEET DATA
Current assets Rs m11,01452,623 20.9%   
Current liabilities Rs m32,06052,022 61.6%   
Net working cap to sales %-108.11.0 -10,782.4%  
Current ratio x0.31.0 34.0%  
Inventory Days Days95120 79.3%  
Debtors Days Days3476 44.0%  
Net fixed assets Rs m29,44085,016 34.6%   
Share capital Rs m705846 83.3%   
"Free" reserves Rs m2,04345,376 4.5%   
Net worth Rs m3,80046,222 8.2%   
Long term debt Rs m9,01841,115 21.9%   
Total assets Rs m46,510142,432 32.7%  
Interest coverage x-0.24.0 -4.8%   
Debt to equity ratio x2.40.9 266.8%  
Sales to assets ratio x0.40.4 99.4%   
Return on assets %-0.86.9 -11.0%  
Return on equity %-146.914.7 -1,001.0%  
Return on capital %-3.714.2 -26.3%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51314,580 51.5%   
Fx outflow Rs m5,6493,600 156.9%   
Net fx Rs m1,86510,980 17.0%   
CASH FLOW
From Operations Rs m1,6828,942 18.8%  
From Investments Rs m-9,860-47,070 20.9%  
From Financial Activity Rs m6,64434,174 19.4%  
Net Cashflow Rs m-1,535-3,655 42.0%  

Share Holding

Indian Promoters % 32.3 71.5 45.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 7.0 65.5%  
FIIs % 3.3 12.6 26.2%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 8.8 628.4%  
Shareholders   84,811 26,511 319.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS